Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update

K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam, C A Prows, E D Kharasch, T C Skaar, Clinical Pharmacogenetics Implementation Consortium, K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam, C A Prows, E D Kharasch, T C Skaar, Clinical Pharmacogenetics Implementation Consortium

Abstract

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

Figures

Figure 1
Figure 1
Codeine metabolism pathway in an individual with cytochrome P450 2D6 (CYP2D6) extensive metabolism. Asterisks (*) denote active metabolites.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren